Skip to main content

Advertisement

Figure 2 | Critical Care

Figure 2

From: Cost-effectiveness of activated protein C in real-life clinical practice

Figure 2

Cost-effectiveness of rhAPC. The figure shows the distribution of the incremental cost-effectiveness ratios in terms of life expectancy (left panel) and of quality-adjusted life-years (QALY; right panel) after 10,000 bootstrap replicates. Quadrants to the right of the y-axis represent the region where treatment with recombinant human activated protein C (rhAPC) is associated with a net gain in effect (85.92%). Quadrants above the x-axis represent the region where treatment is associated with a net increase in cost (100%). Both distributions were thus predominantly in the 'more costly, more effective' upper right quadrant.

Back to article page